Febrile neutropenia: highlighting the role of prophylactic antibiotics and granulocyte colony-stimulating factor during standard dose chemotherapy for solid tumors

Hahn, 1977, Amikacin and cephalothin: empiric regimen for granulocytopenic cancer patients, Antimicrob Agents Chemother, 12, 618, 10.1128/AAC.12.5.618

Elting, 1997, Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials, Clin Infect Dis, 25, 247, 10.1086/514550

Lyman, 1980, The use of lithium carbonate to reduce infection and leukopenia during systemic chemotherapy, N Engl J Med, 302, 257, 10.1056/NEJM198001313020503

Trumpler, 1989, Antibacterial prophylaxis with lactoferrin in neutropenic patients, Eur J Clin Microbiol Infect Dis, 8, 310, 10.1007/BF01963459

Lord, 1989, The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo, Proc Natl Acad Sci U S A, 86, 9499, 10.1073/pnas.86.23.9499

Engels, 1998, Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis, J Clin Oncol, 16, 1179, 10.1200/JCO.1998.16.3.1179

Korten, 1993, Impact of the fluoroquinolones on gastrointestinal flora, Drugs, 45, 125, 10.2165/00003495-199300453-00021

Cullen, 2005, Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas, N Engl J Med, 353, 988, 10.1056/NEJMoa050078

Bucaneve, 2005, Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia, N Engl J Med, 353, 977, 10.1056/NEJMoa044097

Zinner, 1999, Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on Gram-positive and resistant bacteria, Clin Infect Dis, 29, 490, 10.1086/598620

Cruciani, 2003, Reappraisal with meta-analysis of the addition of Gram-positive prophylaxis to fluoroquinolone in neutropenic patients, J Clin Oncol, 21, 4127, 10.1200/JCO.2003.01.234

Tjan-Heijnen, 2001, Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study, Ann Oncol, 12, 1359, 10.1023/A:1012545507920

Gafter-Gvili, 2005, Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients, Ann Intern Med, 142, 979, 10.7326/0003-4819-142-12_Part_1-200506210-00008

Crawford, 1991, Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer, N Engl J Med, 325, 164, 10.1056/NEJM199107183250305

Trillet-Lenoir, 1993, Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy, Eur J Cancer, 29A, 319, 10.1016/0959-8049(93)90376-Q

Lyman, 2002, Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis, Am J Med, 112, 406, 10.1016/S0002-9343(02)01036-7

Green, 2003, A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy, Ann Oncol, 14, 29, 10.1093/annonc/mdg019

Holmes, 2002, Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer, J Clin Oncol, 20, 727, 10.1200/JCO.2002.20.3.727

Lyman, 2004, The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia, Crit Rev Oncol Hematol, 50, 129, 10.1016/j.critrevonc.2004.01.001

Vogel, 2005, First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study, J Clin Oncol, 23, 1178, 10.1200/JCO.2005.09.102

Kuderer, 2005, Meta-analysis of prophylactic granulocyte colony-stimulating factor (G-CSF) in cancer patients receiving chemotherapy [abstract], Proc Am Soc Clin Oncol, 23:, 16s

Schroder, 1999, Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B, J Antimicrob Chemother, 43, 741, 10.1093/jac/43.5.741

Bennett, 1995, Free-riding and the prisoner's dilemma: problems in funding economic analyses of phase III cancer clinical trials, J Clin Oncol, 13, 2457, 10.1200/JCO.1995.13.9.2457

Timmer-Bonte, 2005, Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch randomized phase III study, J Clin Oncol, 23, 7974, 10.1200/JCO.2004.00.7955

von Minckwitz, 2005, Primary prophylaxis with 3 weekly pegfilgrastim and ciprofloxacin effectively prevent (febrile) neutropenia and infection during neoadjuvant chemotherapy with docetaxel/doxorubicin/cyclophosphamide (TAC) in breast cancer patients [abstract], Proc Am Soc Clin Oncol, 23, 8008, 10.1200/jco.2005.23.16_suppl.8008

Maiche, 1993, Granulocyte colony-stimulating factor (G-CSF) with or without a quinolone in the prevention of infection in cancer patients, Eur J Cancer, 29A, 1403, 10.1016/0959-8049(93)90011-4

Lalami, 2004;, A prospective randomised evaluation of G-CSF or G-CSF plus oral antibiotics in chemotherapy-treated patients at high risk of developing febrile neutropenia, Support Care Cancer, 12, 725, 10.1007/s00520-004-0658-6

Smith, 2002, A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK, Ann Oncol, 13, 1590, 10.1093/annonc/mdf275

Tjan-Heijnen, 2003, Economic evaluation of antibiotic prophylaxis in small-cell lung cancer patients receiving chemotherapy: an EORTC double-blind placebo-controlled phase III study (08923), Ann Oncol, 14, 248, 10.1093/annonc/mdg073

Lyman, 1993, Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy, J Natl Cancer Inst, 85, 488, 10.1093/jnci/85.6.488

Ozer, 2000, 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel, J Clin Oncol, 18, 3558, 10.1200/JCO.2000.18.20.3558

Lyman, 1998, The economics of febrile neutropenia: implications for the use of colony-stimulating factors, Eur J Cancer, 34, 1857, 10.1016/S0959-8049(98)00222-6

Calhoun, 2005, Granulocyte colony-stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer: the 40% rule revisited, Pharmacoeconomics, 23, 767, 10.2165/00019053-200523080-00003

Cosler, 2004, Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy, Pharmacotherapy, 24, 488, 10.1592/phco.24.5.488.33360

Doorduijn, 2004, Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma, Haematologica, 89, 1109

Hackshaw, 2004, Are prophylactic haematopoietic growth factors of value in the management of patients with aggressive non-Hodgkin's lymphoma?, Br J Cancer, 90, 1302, 10.1038/sj.bjc.6601708

Messori, 1996, G-CSF for the prophylaxis of neutropenic fever in patients with small cell lung cancer receiving myelosuppressive antineoplastic chemotherapy: meta-analysis and pharmacoeconomic evaluation, J Clin Pharmacol Ther, 21, 57, 10.1111/j.1365-2710.1996.tb00001.x

Hughes, 2002, 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer, Clin Infect Dis, 34, 730, 10.1086/339215

Radberg, 1990, Development of quinolone-imipenem cross resistance in Pseudomonas aeruginosa during exposure to ciprofloxacin, Antimicrob Agents Chemother, 34, 2142, 10.1128/AAC.34.11.2142

Kern, 2005, Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia, Eur J Clin Microbiol Infect Dis, 24, 111, 10.1007/s10096-005-1278-x

Reuter, 2005, Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies, Clin Infect Dis, 40, 1087, 10.1086/428732

Crawford, 2004, Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management, Cancer, 100, 228, 10.1002/cncr.11882

Lyman, 2003, Balancing the benefits and costs of colony-stimulating factors: a current perspective, Semin Oncol, 30, 10, 10.1016/S0093-7754(03)00312-9

Lyman, 2003, Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy, Leuk Lymphoma, 44, 2069, 10.1080/1042819031000119262

Lyman, 2003, Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma, Cancer, 98, 2402, 10.1002/cncr.11827

Crawford, 2005, Risk of neutropenic events during the first cycle of systemic cancer chemotherapy: results from a prospective study [abstract], Support Care Cancer, 13, 426

Martin, 2005, Adjuvant docetaxel for node-positive breast cancer, N Engl J Med, 352, 2302, 10.1056/NEJMoa043681

Pettengell, 1992, Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial, Blood, 80, 1430, 10.1182/blood.V80.6.1430.1430

Sternberg, 2001, Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924, J Clin Oncol, 19, 2638, 10.1200/JCO.2001.19.10.2638

Nabholtz, 2002, Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial, Clin Breast Cancer, 3, 268, 10.3816/CBC.2002.n.030

Mego, 2005, Prevention of febrile neutropenia in cancer patients by probiotic strain Enterococcus faecium M-74. Pilot study phase I, Neoplasma, 52, 159

Garami, 2004, Fermented wheat germ extract reduces chemotherapy-induced febrile neutropenia in pediatric cancer patients, J Pediatr Hematol Oncol, 26, 631, 10.1097/01.mph.0000141897.04996.21

Spielberger, 2004, Palifermin for oral mucositis after intensive therapy for hematologic cancers, N Engl J Med, 351, 2590, 10.1056/NEJMoa040125